- Home
- PAXS vs YMAB Comparison
PAXS vs YMAB Comparison
Compare PAXS & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAXS
- YMAB
- Stock Information
- Founded
- PAXS 2021
- YMAB 2015
- Country
- PAXS United States
- YMAB United States
- Employees
- PAXS N/A
- YMAB N/A
- Industry
- PAXS Investment Managers
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- PAXS Finance
- YMAB Health Care
- Exchange
- PAXS Nasdaq
- YMAB Nasdaq
- Market Cap
- PAXS 757.3M
- YMAB 631.1M
- IPO Year
- PAXS N/A
- YMAB 2018
- Fundamental
- Price
- PAXS $16.31
- YMAB $14.20
- Analyst Decision
- PAXS
- YMAB Strong Buy
- Analyst Count
- PAXS 0
- YMAB 8
- Target Price
- PAXS N/A
- YMAB $21.38
- AVG Volume (30 Days)
- PAXS 195.0K
- YMAB 229.5K
- Earning Date
- PAXS 01-01-0001
- YMAB 11-11-2024
- Dividend Yield
- PAXS 11.72%
- YMAB N/A
- EPS Growth
- PAXS N/A
- YMAB N/A
- EPS
- PAXS N/A
- YMAB N/A
- Revenue
- PAXS N/A
- YMAB $86,546,000.00
- Revenue This Year
- PAXS N/A
- YMAB $11.00
- Revenue Next Year
- PAXS N/A
- YMAB $19.38
- P/E Ratio
- PAXS N/A
- YMAB N/A
- Revenue Growth
- PAXS N/A
- YMAB 1.84
- 52 Week Low
- PAXS $12.57
- YMAB $4.69
- 52 Week High
- PAXS $15.93
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- PAXS 45.26
- YMAB 53.95
- Support Level
- PAXS $16.03
- YMAB $14.04
- Resistance Level
- PAXS $16.79
- YMAB $15.10
- Average True Range (ATR)
- PAXS 0.28
- YMAB 0.72
- MACD
- PAXS -0.10
- YMAB 0.06
- Stochastic Oscillator
- PAXS 23.14
- YMAB 62.34
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.